Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FHTX NASDAQ:PHVS NYSE:RCUS NYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFHTXFoghorn Therapeutics$5.77+7.1%$5.37$2.94▼$10.25$326.18M3.0580,552 shs110,354 shsPHVSPharvaris$23.05+4.9%$21.37$11.51▼$26.33$1.21B-2.8119,456 shs259,519 shsRCUSArcus Biosciences$12.22+5.7%$9.71$6.50▼$18.98$1.30B0.82734,868 shs1.10 million shsZYMEZymeworks$15.05+6.9%$13.63$9.03▼$17.70$1.13B1.27528,693 shs627,107 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFHTXFoghorn Therapeutics0.00%+14.03%+15.86%+29.37%-27.60%PHVSPharvaris0.00%+6.47%+13.44%+37.37%+33.16%RCUSArcus Biosciences0.00%+15.34%+31.19%+22.26%-25.12%ZYMEZymeworks0.00%+1.62%+23.77%+19.44%+29.85%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFHTXFoghorn Therapeutics$5.77+7.1%$5.37$2.94▼$10.25$326.18M3.0580,552 shs110,354 shsPHVSPharvaris$23.05+4.9%$21.37$11.51▼$26.33$1.21B-2.8119,456 shs259,519 shsRCUSArcus Biosciences$12.22+5.7%$9.71$6.50▼$18.98$1.30B0.82734,868 shs1.10 million shsZYMEZymeworks$15.05+6.9%$13.63$9.03▼$17.70$1.13B1.27528,693 shs627,107 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFHTXFoghorn Therapeutics0.00%+14.03%+15.86%+29.37%-27.60%PHVSPharvaris0.00%+6.47%+13.44%+37.37%+33.16%RCUSArcus Biosciences0.00%+15.34%+31.19%+22.26%-25.12%ZYMEZymeworks0.00%+1.62%+23.77%+19.44%+29.85%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFHTXFoghorn Therapeutics 3.17Buy$10.6784.86% UpsidePHVSPharvaris 2.80Moderate Buy$34.0047.51% UpsideRCUSArcus Biosciences 2.75Moderate Buy$21.1473.02% UpsideZYMEZymeworks 2.90Moderate Buy$21.4342.38% UpsideCurrent Analyst Ratings BreakdownLatest FHTX, PHVS, RCUS, and ZYME Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025PHVSPharvarisZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/13/2025PHVSPharvarisJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$55.00 ➝ $52.008/11/2025ZYMEZymeworksCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$19.00 ➝ $22.008/7/2025RCUSArcus BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$26.00 ➝ $25.007/3/2025ZYMEZymeworksHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$13.006/11/2025PHVSPharvarisGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$32.00(Data available from 9/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFHTXFoghorn Therapeutics$22.60M14.43N/AN/A($0.82) per share-7.04PHVSPharvarisN/AN/AN/AN/A$5.54 per shareN/ARCUSArcus Biosciences$258M5.04N/AN/A$5.30 per share2.31ZYMEZymeworks$122.87M9.21N/AN/A$6.63 per share2.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFHTXFoghorn Therapeutics-$86.62M-$1.19N/AN/AN/A-311.90%N/A-28.00%11/3/2025 (Estimated)PHVSPharvaris-$145.24M-$3.36N/AN/AN/AN/A-69.09%-63.34%11/12/2025 (Estimated)RCUSArcus Biosciences-$283M-$3.17N/AN/AN/A-109.56%-55.96%-25.73%11/5/2025 (Estimated)ZYMEZymeworks-$118.67M-$0.97N/AN/AN/A-182.75%-23.00%-18.04%10/30/2025 (Estimated)Latest FHTX, PHVS, RCUS, and ZYME EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025PHVSPharvaris-$0.87-$0.94-$0.07-$0.94N/AN/A8/7/2025N/AZYMEZymeworks-$0.52$0.03+$0.55N/A$17.18 million$48.73 million8/6/2025Q2 2025RCUSArcus Biosciences-$1.14-$1.1053+$0.0347N/A$32.86 million$160.00 million8/5/2025Q2 2025FHTXFoghorn Therapeutics-$0.31-$0.28+$0.03-$0.28$7.62 million$7.56 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFHTXFoghorn TherapeuticsN/AN/AN/AN/AN/APHVSPharvarisN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFHTXFoghorn TherapeuticsN/A2.622.62PHVSPharvarisN/A8.338.33RCUSArcus Biosciences0.184.504.50ZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFHTXFoghorn Therapeutics61.55%PHVSPharvarisN/ARCUSArcus Biosciences92.89%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipFHTXFoghorn Therapeutics7.58%PHVSPharvarisN/ARCUSArcus Biosciences9.60%ZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFHTXFoghorn Therapeutics12056.53 million52.25 millionOptionablePHVSPharvaris3052.29 millionN/ANot OptionableRCUSArcus Biosciences500106.43 million96.21 millionOptionableZYMEZymeworks46075.17 million67.56 millionOptionableFHTX, PHVS, RCUS, and ZYME HeadlinesRecent News About These CompaniesBrokers Set Expectations for Zymeworks FY2025 EarningsSeptember 7 at 6:51 AM | marketbeat.comEcoR1 Capital LLC Purchases 2,231,469 Shares of Zymeworks Inc. $ZYMESeptember 6 at 8:27 AM | marketbeat.comTrexquant Investment LP Has $2.63 Million Stake in Zymeworks Inc. $ZYMESeptember 6 at 4:43 AM | marketbeat.comBloom Burton Comments on Zymeworks FY2025 EarningsSeptember 6 at 2:27 AM | americanbankingnews.comZymeworks Inc. (NYSE:ZYME) Receives Average Rating of "Moderate Buy" from AnalystsSeptember 5 at 2:45 AM | marketbeat.comZymeworks (NYSE:ZYME) Shares Gap Down - What's Next?September 4 at 1:23 PM | marketbeat.comADAR1 Capital Management LLC Acquires New Position in Zymeworks Inc. $ZYMESeptember 4 at 7:41 AM | marketbeat.comZymeworks Inc. $ZYME Stake Reduced by Redmile Group LLCSeptember 4 at 7:28 AM | marketbeat.comZymeworks Inc. $ZYME Shares Acquired by Vestal Point Capital LPSeptember 4 at 7:17 AM | marketbeat.comHealth Sector Innovations: From Blood Thinners to Bird Flu OutbreaksSeptember 3, 2025 | devdiscourse.comDZymeworks: Despite T-Cell Engager Setback, ADC Candidates Press OnSeptember 2, 2025 | seekingalpha.comZymeworks drops clinical-stage T-cell engager after assessing benefit-risk profileSeptember 2, 2025 | fiercebiotech.comFZymeworks halts development of cancer drug after trial setbackSeptember 2, 2025 | reuters.comZymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell EngagerSeptember 2, 2025 | globenewswire.comWellington Management Group LLP Reduces Stock Holdings in Zymeworks Inc. $ZYMESeptember 2, 2025 | marketbeat.comNuveen LLC Acquires Shares of 198,812 Zymeworks Inc. $ZYMESeptember 1, 2025 | marketbeat.comVanguard Group Inc. Decreases Stock Position in Zymeworks Inc. $ZYMESeptember 1, 2025 | marketbeat.comTema Etfs LLC Makes New Investment in Zymeworks Inc. $ZYMEAugust 31, 2025 | marketbeat.comWalleye Capital LLC Has $2.95 Million Stake in Zymeworks Inc. $ZYMEAugust 30, 2025 | marketbeat.comAlphaQuest LLC Purchases 28,868 Shares of Zymeworks Inc. $ZYMEAugust 30, 2025 | marketbeat.comZymeworks Reports Q2 Results and FDA ClearanceAugust 19, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFHTX, PHVS, RCUS, and ZYME Company DescriptionsFoghorn Therapeutics NASDAQ:FHTX$5.77 +0.38 (+7.05%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$5.78 +0.01 (+0.09%) As of 09/5/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Pharvaris NASDAQ:PHVS$23.05 +1.07 (+4.87%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$23.10 +0.04 (+0.20%) As of 09/5/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.Arcus Biosciences NYSE:RCUS$12.22 +0.66 (+5.71%) Closing price 09/5/2025 03:59 PM EasternExtended Trading$12.21 -0.01 (-0.08%) As of 09/5/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.Zymeworks NYSE:ZYME$15.05 +0.97 (+6.89%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$15.18 +0.13 (+0.83%) As of 09/5/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Union Pacific: Laying the Tracks for America's Industrial Renewal TransDigm’s Edge: From Spare Parts to Sky-High Profits Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
